TeamDrive
RUS

Tomsk researchers developed new nanosilver catalysts

10 August 2018

GMP News

The Tomsk Polytechnic University (TPU) research team proposed to use catalysts based on silver nanoparticles in liquid-phase oxidation of alcohols. This will allow making the process of alcohol oxidation more ecological and cost-effective, comparing with more traditional high-temperature gas-phase oxidation or with toxic reagents.

In the article, published in the journal Fuel, the researchers proved the possibility to use these catalysts based on silver, on the example of the oxidation of octanol and betulin. The derivatives of these substances are valuable products for the chemical, pharmaceutical, and cosmetic industries.

“In the organic synthesis, the alcohol oxidation in the liquid phase is a more green approach, comparing to that in the gas phase. Firstly, it proceeds at lower temperatures, making it less energy-consuming. Secondly, there are no products of complete oxidation, i.e., water and CO2, whose formation indicates a decrease in the reaction selectivity and a decrease in the output of the target product as well”, explained Ekaterina Kolobova, one of the authors of the article, a senior researcher of the Research School of Chemistry & Applied Biomedical Sciences.

Scientists pay particular attention to the use of gold and metals of the platinum group as catalysts in such processes. In the studies TPU scholars used catalysts that are a substrate of titanium oxide. It can be pure or modified by other elements, for example, cerium oxide with silver nanoparticles deposited on its surface.

Using these recently developed nanosilver catalysts the research team has succeeded in obtaining one of the oxo-derivatives of betulin – betulon under conditions close to green chemistry. It means at a temperature below 150°C and avoiding alkaline and initiating additives, which application can entail the formation of undesirable and toxic waste.

Source


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more